Aptevo Therapeutics Inc. (NASDAQ:APVO) Expected to Announce Earnings of -$1.15 Per Share

Equities research analysts predict that Aptevo Therapeutics Inc. (NASDAQ:APVOGet Rating) will report earnings per share of ($1.15) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aptevo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.37). Aptevo Therapeutics posted earnings of ($1.74) per share during the same quarter last year, which would indicate a positive year over year growth rate of 33.9%. The business is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Aptevo Therapeutics will report full-year earnings of ($4.44) per share for the current financial year, with EPS estimates ranging from ($4.94) to ($3.93). For the next year, analysts forecast that the firm will post earnings of ($4.45) per share, with EPS estimates ranging from ($4.69) to ($4.20). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVOGet Rating) last released its quarterly earnings results on Thursday, March 24th. The biotechnology company reported ($1.27) EPS for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.03. Aptevo Therapeutics had a negative return on equity of 357.62% and a negative net margin of 231.51%.

A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Tuesday, March 29th. StockNews.com assumed coverage on Aptevo Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating for the company.

Large investors have recently made changes to their positions in the company. Morgan Stanley raised its position in Aptevo Therapeutics by 163.4% during the second quarter. Morgan Stanley now owns 8,364 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 5,189 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Aptevo Therapeutics during the third quarter valued at approximately $211,000. Franklin Resources Inc. purchased a new position in Aptevo Therapeutics during the third quarter valued at approximately $242,000. Marshall Wace LLP purchased a new position in Aptevo Therapeutics during the first quarter valued at approximately $33,000. Finally, Geode Capital Management LLC raised its position in Aptevo Therapeutics by 2.6% during the third quarter. Geode Capital Management LLC now owns 39,924 shares of the biotechnology company’s stock valued at $616,000 after acquiring an additional 1,007 shares in the last quarter. Hedge funds and other institutional investors own 82.56% of the company’s stock.

Aptevo Therapeutics stock opened at $4.26 on Friday. The stock has a 50-day moving average of $5.24 and a two-hundred day moving average of $7.99. The company has a current ratio of 1.51, a quick ratio of 1.51 and a debt-to-equity ratio of 3.05. Aptevo Therapeutics has a one year low of $3.97 and a one year high of $31.76.

About Aptevo Therapeutics (Get Rating)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.

Recommended Stories

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.